Wolff WI, Shinya H. Polypectomy via the fiberoptic colonoscope: removal of neoplasms beyond reach of the sigmoidoscope. N Engl J Med. 1973;288:329–32.
Beahrs O. The medical history of President Ronald Reagan. J Am Coll Surg. 1994;178:86–96.
Sorensen RH, Farnsworth GS, Roberts JE, et al. President Reagan’s life saving colectomy and subsequent historical implications. Mil Med. 2014;179:704–7.
Thomas H Maugh II. Reagan’s surgery for colon cancer breaks a taboo, brings a floodtide of calls. Los Angeles Times, 1985.
Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.
Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology. 2014;147:502–26.
Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.
Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing: results for 68,308 subjects. Scand J Gastroenterol. 1994;29:468–73.
Mandel JS, Bond JH, Church TR, et al. Reducing mortal colorectal cancer screen fecal occult blood. N Engl J Med. 1993;328:1365–7.
Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet . 1996;348:1467–71.
Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American college of physicians. Ann Intern Med. 1997;126:811–22.
Shaukat A, Mongin Sj, Geisser MS. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106–14.
Collins J, Lieberman D, Durbin T, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81–85.
Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–81.
Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–96.
Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594–642.
Virginia's Legislative Information System. Code of Virginia, 38. 2-3418.7:1: Coverage for colorectal cancer screening. https://law.lis.virginia.gov/vacode/title38.2/chapter34/section38.2-3418.7:1. April 23, 2018.
Cram P, Fendrick AM, Inadomi J, et al. The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med. 2003;163:1601–5.
Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology . 1997;112:24–28.
Bjorkman DJ, Popp JW Jr. Measuring the quality of endoscopy. Am J Gastroenterol. 2006;101:864–5.
Cotton PB, Barkun A, Ginsberg G, et al. Diagnostic endoscopy: 2020 vision. Gastrointest Endosc. 2006;64:395–8.
GI Quality Improvement Consortium. http://giquic.gi.org/what-is-giquic.asp. April 23, 2018.
Pike IM, Eisen GM, Greenwald DA, et al. Increasing adenoma detection rate over time in a national benchmarking registry. Oral presentation, Digestive Diseases Week annual conference. 2017.
Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795–803.
Kaminski MF, Wieszczy P, Rupinski M, et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. Gastroenterology. 2017;153:98–105.
National Colorectal Cancer Roundtable. 80% by 2018 campaign. http://nccrt.org/what-we-do/80-percent-by-2018/. April 23, 2018.
White A, Thompson TD, White MC, et al. Cancer screening test use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:201–6.
Joseph DA, King JB, Richards TB, et al. Use of colorectal cancer screening tests by state. Prev Chronic Dis. 2018;15:170535.
Siegel R, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.
Williams R, White P, Nieto J, et al. Committee on minority affairs and cultural diversity, american college of gastroenterology. Colorectal cancer in African Americans: an update. Clin Transl Gastroenterol. 2016;7:e185.
Ashktorab H, Vimenay K, Brim H, et al. Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? Dig Dis Sci. 2016;61:3026–30.
Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307–23.
Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109:djw322.
Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018.
Crockett SD, Snover DC, Ahnen DJ, et al. Sessile serrated adenomas: an evidence-based guide to management. Clin Gastroenterol Hepatol. 2015;13:11–26.
IJspeert JE, Tutein Nolthenius CJ, Kuipers EJ, et al. CT-colonography vs. colonoscopy for detection of high-risk sessile serrated polyps. Am J Gastroenterol. 2016;111:516–22.
Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.
Gralnek IM, Siersema PD, Halpern Z, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. Lancet Oncol. 2014;15:353–60.
Leufkens AM, DeMarco DC, Rastogi A, et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc. 2011;73:480–9.
Triantafyllou K, Polymeros D, Apostolopoulos P, et al. Endocuff-assisted colonoscopy is associated with a lower adenoma miss rate: a multicenter randomized tandem study. Endoscopy. 2017;49:1051–60.
Dik VK, Gralnek IM, Segol O, et al. Multicenter, randomized, tandem evaluation of EndoRings colonoscopy—results of the CLEVER study. Endoscopy. 2015;47:1151–8.
Halpern Z, Gross SA, Gralnek IM, et al. Comparison of adenoma detection and miss rates between a novel balloon colonoscope and standard colonoscopy: a randomized tandem study. Endoscopy. 2015;47:238–44.
Brand EC, Dik VK, Van Oijen MGH, et al. Missed adenomas with behind-folds visualizing colonoscopy technologies compared with standard colonoscopy: a pooled analysis of 3 randomized back-to-back tandem colonoscopy studies. Gastrointest Endosc. 2017;86:376–85.
Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.
Johnson DA, Barclay RL, Mergener K, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS ONE. 2014;9:e98238.
Sonoda H, Kohnoe S, Yamazato T, et al. Colorectal cancer screening with odour material by canine scent detection. Gut. 2011;60:814–9.
Nakhleh MK, Amal H, Jeries R, et al. Diagnosis and classification of 17 diseases from 1404 subjects via pattern analysis of exhaled molecules. ACS Nano. 2017;11:112–25.
Hakim M, Broza YY, Barash O, et al. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev. 2012;112:5949–66.
Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103:542–51.
Peng G, Tisch U, Adams O, et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 2009;4:669–73.
Amal H, Leja M, Funka K, et al. Breath testing as potential colorectal cancer screening tool. Int J Cancer. 2016;138:229–36.
de Meij T, Larbi I, van der Schee MP, et al. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by faecal volatile markers; proof of principle study. Int J Cancer. 2013;134:1132–8.
Altamore DF, Di Lena M, Porcelli F. Exhaled volatile organic compounds detect patients with colon cancer. Br J Surg. 2013;100:144–50.